David R. Oveisi, MD emphasizes the significance of increased awareness about the availability of CAR T-cell therapies in early-relapse settings. These therapies have provided additional options for patients with relapsed/refractory multiple myeloma. The FDA's approval of ide-cel and cilta-cel in earlier indications has led to a need for careful counseling of eligible patients.

Unlocking New Horizons in Multiple Myeloma Treatment with CAR T-Cell Therapies

Impact on Treatment Decision-Making

Determining eligibility for autologous stem cell transplant is straightforward for most patients. However, for those who are frail or older, CAR T-cell therapy becomes a crucial option. The prior label indications often led to patients being in poor condition by the time they received CAR T-cell therapy. In the earlier-relapse setting, it is especially important to consider CAR T-cell therapy for patients who may not have another chance. Oveisi discusses the factors influencing treatment decisions, such as patient input and travel distance.

For example, in some cases, older patients in their 80s can benefit from CAR T-cell therapy if they are still fit and functional. This shows that age alone should not be a barrier to considering these therapies.

Managing Adverse Effects

Adverse effects associated with CAR T-cell therapy can be serious, especially neurocognitive and movement disorders. Understanding which patients are at higher risk and how to mitigate these effects is crucial. By reducing the myeloma disease burden before CAR T-cell therapy, the risk of high-grade cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome can be decreased.

For instance, using effective bridging therapies to lower the disease burden allows for a more controlled introduction of CAR T-cells and reduces the occurrence of unusual adverse events.

Differences in Patient Populations in Clinical Trials

In the phase 3 CARTITUDE-4 and KarMMa-3 studies, cilta-cel showed a higher response rate and longer duration of action compared to ide-cel. The patient populations in the two trials differed, with cilta-cel including less refractory patients and fewer prior lines of therapy. The bridging therapies also varied between the studies.

These differences highlight the importance of interpreting trial results carefully and not overgeneralizing. Each patient's situation is unique, and these factors need to be considered when selecting a treatment.

Long-Term Management and Monitoring

After CAR T-cell therapy, the focus is on long-term management and monitoring. This includes ensuring hematopoietic recovery, preventing infections, and providing supportive care. Growth factors and periodic transfusions are commonly used to support patients.

For example, most patients achieve transfusion independence by 3 months. Prophylactic IVIg and antiviral suppression are also important to keep patients healthy. Regular monitoring of CD4 counts and other parameters helps detect any potential issues early.

Counseling Patients

It is essential to educate patients about the CAR T-cell therapy process, including the potential for adverse effects and the need for chemotherapy. Understanding the patient's social situation is also crucial to ensure their safety during the recovery period.

For instance, if a patient lives alone or has limited support, it may be necessary to make additional arrangements to ensure their well-being. Early consideration of referral for CAR T-cell therapy can be beneficial for high-risk patients.

In conclusion, CAR T-cell therapies have expanded treatment options for multiple myeloma patients. Careful consideration of various factors and proper management are essential for optimal outcomes. These therapies offer hope to many patients and are an important part of the treatment paradigm.